Delving into the Latest Updates on Amsacrine with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

4'-(9-Acridinylamino)-3'-methoxymethanesulfonanilide, 4'-(9-Acridinylamino)methanesulfon-m-anisidide, 4'-(9-Acridinylamino)methanesulfon-meta-anisidide

+ [23]

Target

Top II

Mechanism

Top II inhibitors(Topoisomerase II inhibitors)

Therapeutic Areas

NeoplasmsHemic and Lymphatic Diseases

Active Indication

Leukemia

Inactive Indication-

Originator Organization-

Active Organization

Searchlight Pharma, Inc.Startup

Inactive Organization-

Drug Highest PhaseApproved

First Approval Date

CA (31 Dec 1983),

Leukemia

RegulationOrphan Drug (US)

Login to view timeline

Structure

Molecular FormulaC21H20ClN3O3S

InChIKeyWDISRLXRMMTXEV-UHFFFAOYSA-N

CAS Registry54301-15-4

View All Structures (2)

This trial aims to find the MTD of Venetoclax when added to Fludarabin, Amsacrine and Ara-C + Treosulfan and to evaluate whether the addition of Venetoclax to sequential conditioning with FLAMSA + Treosulfan is safe for allogeneic blood stem cell transplantation in patients with high-risk MDS, CMML or sAML (FLAMSAClax)

Start Date26 Jun 2023

Sponsor / Collaborator

Heinrich-Heine-Universität Düsseldorf

NCT03765541 / RecruitingPhase 3IIT

Dexamethasone Plus Salvage Chemotherapy Versus Salvage Chemotherapy Alone in Patients With First Relapsed or Refractory Acute Myeloid Leukemia: a Randomized, Controlled, Open-label, Multicenter, Phase III Study

Recent preclinical and retrospective clinical data have suggested that dexamethasone might sensitize leukemic cells to chemotherapy-induced cell death and thus limit the risk of leukemic regrowth and relapse. Moreover, it has been experimentally shown that leukemic cells in acute myeloid leukemia patients who relapse become sensitive to glucocorticoids treatment highlighting a novel potential role for dexamethasone in relapsed or refractory acute myeloid leukemia (R/R).
This study was designed to determine whether adding dexamethasone to standard salvage therapy in the treatment of relapsed/refractory acute myeloid leukemia in adult patients (intensive chemotherapy amsacrine-cytarabine or azacitidine according to investigator's willingness) results in a significant improvement of the overall survival.

Start Date13 Jan 2020

Sponsor / Collaborator-

100 Clinical Results associated with Amsacrine

Login to view more data

100 Translational Medicine associated with Amsacrine

Login to view more data

100 Patents (Medical) associated with Amsacrine

Login to view more data

1,362

Literatures (Medical) associated with Amsacrine

01 Nov 2024·International Journal of Pediatric Otorhinolaryngology

The AMSA® manosonic nebulizer for ENT disease among children in Poland

Article

Author: Skarżyńska, Magdalena Beata ; Skarżyński, Piotr Henryk ; Gos, Elżbieta ; Sanfins, Milaine Dominici ; Szkiełkowska, Agata ; Hartwich, Patryk ; Skarzynska, Magdalena Beata

INTRODUCTIONThe AMSA® manosonic nebulizer uses acoustic vibration and a flow of air to create an aerosol from a solution or suspension of a drug. The aerosol created this way is claimed to have enhanced penetration and drug delivery. It is administered under short-term overpressure, meaning that the aerosol is able to penetrate into the middle ear through the Eustachian tube (ET).PURPOSEof the study: The aim of this study is to identify the active substances used in AMSA® manosonic nebulization for treating common ENT diseases in children aged 2-17 years and to evaluate the overall effectiveness of AMSA® manosonic nebulization in this context. Assessments were done by comparing conditions before and after nebulization using the following tests: (1) Eustachian tube function test, (2) tympanometry, and (3) otoscopy.MATERIAL AND METHODSThis study was a retrospective study with ethics committee consent. 129 children, comprising 56 girls and 73 boys. They were aged between 2 and 17 years, with a mean age of 6.9 years (SD = 3.0). There were 74 children up to 6 years and 55 children over 6 years of age. Children had the following conditions: (1) chronic otitis media with effusion, OME (n = 86), (2) Eustachian tube dysfunction, ETD (n = 34) (3) Other conditions (e.g. cholesteatoma, retraction pocket), (n = 9). Combination of medicines administered in this study was: Budesonide + ambroxol (with or without NaCl), Budesonide (with or without NaCl), Budesonide + N-acetylcysteine (with or without NaCl), Budesonide + hyaluronic acid, Budesonide + ambroxol (with hyaluronic acid), Ambroxol (with or without NaCl).RESULTSThe number of nebulizations ordered was between 1 and 20 treatments, but most commonly, pa-tients were given a nebulization series of 10 treatments. This was the case for 80.6 % of the patients. Most patients with OME and ETD had 10 treatments ordered (79 % and 79.5 %, respectively), while all patients with other conditions had 10 treatments. Analysis of the tympanometry results was done in terms of the number of affected ears (not by individual). There were 210 ears with complete tympanometry (both pre and post), including 142 ears with OME, 54 with ETD, and 14 others. Statistically significant changes (improvements) after AMSA nebulizations were found for statistic compliance and middle ear pressure. Otoscopy assessments were done in all ears. The results were abnormal in 155 ears (73.8 %) and normal in 55 ears (26.2 %). After AMSA nebulizations, the number of abnormal results decreased to 117 ears (55.7 %) and normal results were found in 93 ears (44.7 %).CONCLUSIONUse of the AMSA manosonic nebulizer appears to be an effective way of improving chronic medical conditions in children - such as chronic otitis media with effusion and Eustachian tube defect - but only if patient compliance can be achieved. The most frequently used active substance was budesonide, irrespective of whether additional secretolic/mucolytic agent was administered.

14 Oct 2024·Nucleic Acids Research

Correction to ‘Structural basis for difunctional mechanism of m-AMSA against African swine fever virus pP1192R’

14 Oct 2024·Nucleic Acids Research

Structural basis for difunctional mechanism of m-AMSA against African swine fever virus pP1192R

Article

Author: Pang, Erqi ; Liu, Sheng ; Peng, Guorui ; Fu, Lifeng ; Cheng, Yingxian ; Li, Xiaomei ; Liu, Ruili ; Li, Meilin ; Qi, Jianxun ; Wang, Han ; Wang, Yanli ; Gao, George Fu ; Sun, Junqing ; Qu, Xiao ; Qiu, Hua-Ji ; Li, Lian-Feng ; Ran, Jiaqi ; Wang, Yanjin ; Li, Su

AbstractThe African swine fever virus (ASFV) type II topoisomerase (Topo II), pP1192R, is the only known Topo II expressed by mammalian viruses and is essential for ASFV replication in the host cytoplasm. Herein, we report the structures of pP1192R in various enzymatic stages using both X-ray crystallography and single-particle cryo-electron microscopy. Our data structurally define the pP1192R-modulated DNA topology changes. By presenting the A2+-like metal ion at the pre-cleavage site, the pP1192R–DNA–m-AMSA complex structure provides support for the classical two-metal mechanism in Topo II-mediated DNA cleavage and a better explanation for nucleophile formation. The unique inhibitor selectivity of pP1192R and the difunctional mechanism of pP1192R inhibition by m-AMSA highlight the specificity of viral Topo II in the poison binding site. Altogether, this study provides the information applicable to the development of a pP1192R-targeting anti-ASFV strategy.

100 Deals associated with Amsacrine

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D02321	Amsacrine	L01XX01	DB00276

R&D Status

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Leukemia	CA	Searchlight Pharma, Inc.Startup	31 Dec 1983

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


P273 (EBMT2023)	Not Applicable	Neoplasms	41	FLAMSA+Alkylator+Venetoclax	hdynwrnukh(jhycxppdmw) = poutbfjipp turpdfqarr (jlpmddukma ) View more	-	23 Apr 2023
EBMT2022	Not Applicable	-	11	Venetoclax + FLAMSA + alkylator	okhfmutunf(nasdpihevr) = rjhkliblzo ljsyyajxyv (isopuhrfoa ) View more	-	19 Mar 2022
NCT00180102 (AML2003, Pubmed \| J Urol)	Phase 4	Acute Myeloid Leukemia Consolidation	-	Standard high-dose cytarabine consolidation	(kglbmzgfrs) = diefkqofpj vwpmwymufu (iudkjoqtsl ) View more	Negative	10 Jun 2013
NCT00180102 (AML2003, Pubmed \| J Urol)	Phase 4	Acute Myeloid Leukemia Consolidation	-	Multiagent consolidation with mitoxantrone and amsacrine	(kglbmzgfrs) = tlxeyxmmge vwpmwymufu (iudkjoqtsl ) View more	Negative	10 Jun 2013
Tandem Meetings ASTCT and CIBMTR2012	Not Applicable	Refractory High Risk Myelodysplastic Syndrome	40	FLAMSA sequential chemotherapy	(yrsnpditwi) = xmtjwqlhgs vgohzpqmpk (wbskaidsul, 17 - 52) View more	Positive	01 Feb 2012
Tandem Meetings ASTCT and CIBMTR2012	Not Applicable	Refractory High Risk Myelodysplastic Syndrome	40	Flamsa (Reduced-Intensity Conditioning (RIC) regimen with TBI)	wliaolalrg(yxzrroktyz) = qfkzlqhuip pkbylocuuf (knqpbzqjaw, 8 - 20)	Positive	01 Feb 2012